Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

  • ID: 3816875
  • Report
  • Region: Global
  • 340 Pages
  • Kalorama Information
1 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Mylan
  • Pfizer
  • MORE

The pharmaceutical market has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report provides:

Corporate Summary:

  • Total Company Revenue and Total R&D Spending 2011-2015
  • Break-up of Sales by Region, 2015
  • Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
  • Leading Pharmaceutical Products, 2015 Sales
  • Late Stage Product Pipeline
  • Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
  • Corporate Development Details

Despite the new approaches, new technologies and a wealth of new information, drug R&D is still challenged by understanding exactly how drugs will work and why they may fail. Target validation remains a quandary as well. Thus, the hurdle of getting past Phase III trials and launching more NMEs continues. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:

  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • The Role of Contract Research Organizations

The report also looks at market trends and values by therapeutic area, providing information on the following segments:

  • Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
  • Top 5 Neurotherapeutic Companies, 2015 Sales
  • Top 5 Infection Treatment Companies, 2015 Sales
  • Top 5 Oncology Companies, 2015 Sales
  • Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
  • Top 5 Other Drug Companies, 2015 Sales

In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. Data provided include:

  • Global Pharmaceutical Projects in Development by Therapeutic Segment
  • Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market % Change by Therapeutic Segment, 2014-2015
  • Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
  • Top Companies by 2015 Pharmaceutical Sales Growth
  • Global Pharmaceutical Market, Sales Growth by Company, 2014- 2015
  • Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales, 2015 Compared to 2011 and 2013
  • Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
  • Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025-based on late stage development projects evaluated
  • Evaluating Pharmaceutical Company Growth, 2015-2025
  • Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
  • International Population Trend Age 65+

For the purpose of this study, the publisher has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals, diagnostics, devices, chemicals, agriculture and animal health. These are areas where many of these companies also compete with significant market shares.

Also, despite an in-depth interview process and complete review of the top 25 pharmaceutical companies' financials and literature, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical sales are not discussed.

This report provides long-term company sales forecasts, which are based on 2015 market conditions. Company forecasts were derived from a combination of pipeline analyses, current product reviews, patent and exclusivity activities, recent merger and alliance impacts, and a number of other factors discovered throughout the writing of this report.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Mylan
  • Pfizer
  • MORE

1. Executive Summary

  • Introduction
  • Scope and Methodology
  • Future Market Opportunity
  • Leading Companies
  • Conclusions

2. Introduction

  • Global Pharmaceutical Market
  • Top 25 Pharmaceutical Companies: An Overview
  • Global Healthcare Spending
  • Aging Population and Impact on Pharmaceutical Markets

3. Trends in Pharmaceutical Research and Development

  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Percent of Approvals
  • Selecting Better Targets
  • Top R&D Spenders
  • The Pipeline Snapshot
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Breakthrough Therapy
  • Pharmaceutical Regulatory Exclusivity
  • Pediatric Extensions
  • The Role of Contract Research Organizations

4. Pfizer, Inc.

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

5. Novartis International AG

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

6. Roche Ltd.

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

7. Merck & Co., Inc.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

8. Sanofi

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

9. Gilead Sciences

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

10. Johnson & Johnson

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

11. GlaxoSmithKline plc

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

12. AstraZeneca plc

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

13. AbbVie, Inc.

  • Company Overview
  • Financial Performance and Investments
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

14. Amgen, Inc.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

15. TEVA Pharmaceutical Industries, Ltd.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

16. Eli Lilly and Company

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

17. Bristol-Myers Squibb Company

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

18. Novo Nordisk

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

19. Bayer AG

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

20. Takeda Pharmaceutical Co., Ltd.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

21. Boehringer Ingelheim GmbH

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

22. Allergan PLC

  • Company Overview
  • Company Financial Performance and Investments
  • Pharmaceutical Business Performance
  • Late Stage Pipeline
  • Growth Strategy

23. Astellas Pharma, Inc.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

24. Mylan, Inc.

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Pipeline
  • Growth Strategy

25. Biogen, Inc.

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Pipeline
  • Growth Strategy

26. Celgene Corporation

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

27. Otsuka Pharmaceutical

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

28. Daiichi Sankyo

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

29. Market Summary and Forecast Analysis

  • Company Overview
  • Market Trends and Values by Therapeutic Area
  • Cardiovascular/Blood Market Analysis
  • Neurotherapeutics Market Analysis
  • Infection Treatments Market Analysis
  • Oncology Market Analysis
  • Respiratory and Inflammation Market Analysis
  • Other Drug Market Analysis
  • Evaluating Changes in 2015 Market Value
  • Year-over-Year Growth Analysis
  • Company Analysis
  • Market Forecast
  • Future Company Outlook

List of Exhibits:
Executive Summary
Table 1-1: Global Pharmaceutical Projects in Development by Therapeutic Segment
Figure 1-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
Table 1-2: Leading Pharmaceutical Companies
Introduction
Figure 2-1: Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
Table 2- 1: Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
Figure 2-2: Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales2015
Table 2-2: Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates
Figure 2-3: International Population Trend Age 65+
Trends in Pharmaceutical Research and Development
Table 3-1: Phases of Clinical Drug Development
Table 3-2: Top R&D Spenders in the Pharmaceutical Industry 2013, 2014 and2015
Figure 3-1: Top 10 R&D Spenders in the Pharmaceutical Industry, 2015 Comparison by Company
Figure 3-2: Company Pipelines by Total Late Stage Development Projects (Top 25 Companies by Revenues)
Figure 3-3: Cardiovascular/Blood Pipeline Leaders, 2015
Figure 3-4: Neurotherapeutics Pipeline Leaders, 2015
Figure 3-5: Infectious Disease Pipeline Leaders, 2015
Figure 3-6: Oncology Pipeline Leaders, 2015
Figure 3-7: Respiratory/Inflammation Pipeline Leaders, 2015
Figure 3-8: Other Therapy Pipeline Leaders, 2015
Table 3-3: Orphan Drug Designations Granted and Approved by the FDA 1983-2016
Table 3-4: Examples of Fast-Track Drugs Withdrawn from Market
Pfizer, Inc.
Table 4-1: Pfizer Corporate Summary
Table 4-2: Pfizer: Total Company Revenue and Total R&D Spending 2011-2015
Figure 4-1: Pfizer: Break-up of Total Revenues by Region, 2015
Figure 4-2: Pfizer: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 4-3: Pfizer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 4-3: Pfizer: Leading Pharmaceutical Products, 2015 Sales
Table 4-4: Pfizer: Late Stage Product Pipeline
Figure 4-4: Pfizer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
Table 4-5: Highlighted Corporate Developments
Novartis International AG
Table 5-1: Novartis Corporate Summary
Table 5-2: Novartis: Total Company Revenue and Total R&D Spending 2011-2015
Figure 5-1: Novartis: Break-up of Sales by Region, 2015
Figure 5-2: Novartis: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 5-3: Novartis: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 5-3: Novartis: Leading Pharmaceutical Products, 2015 Sales
Table 5-4: Novartis: Late Stage Product Pipeline
Figure 5-4: Novartis: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 5-5: Highlighted Corporate Developments
Roche Ltd.
Table 6-1: Roche Corporate Summary
Table 6-2: Roche: Total Company Revenue and Total R&D Spending 2011-2015
Figure 6-1: Roche: Break-up of Sales by Region, 2015
Figure 6-2: Roche: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 6-3: Roche: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 6-3: Roche: Leading Pharmaceutical Products, 2015 Sales
Table 6-4: Roche: Late Stage Product Pipeline
Figure 6-4: Roche: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 6-5: Highlighted Corporate Developments
Merck & Co., Inc.
Table 7-1: Merck Corporate Summary
Table 7-2: Merck: Total Company Revenue and Total R&D Spending 2011-2015
Figure 7-1: Merck: Break-up of Sales by Region, 2015
Figure 7-2: Merck: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 7-3: Merck: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 7-3: Merck: Leading Pharmaceutical Products, 2015 Sales
Table 7-4: Merck: Late Stage Product Pipeline
Figure 7-4: Merck: Late Stage Product Pipeline by Therapeutic
Area-Comparing 2009, 2011, 2013 and 2015
Table 7-5: Highlighted Corporate Developments
Sanofi
Table 8-1: Sanofi Corporate Summary
Table 8-2: Sanofi Total Company Revenue and Total R&D Spending 2011-2015
Figure 8-1: Sanofi: Break-up of Sales by Region, 2015
Figure 8-2: Sanofi: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 8-3: Sanofi: Pharmaceutical Segment Sales jQuery15109608159432631119_1491214110321 2011 through 2015 and Forecasted 2025
Table 8-3: Sanofi: Leading Pharmaceutical Products, 2015 Sales
Table 8-4: Sanofi Late Stage Product Pipeline
Figure 8-4: Sanofi: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
Table 8-5: Highlighted Corporate Developments
Gilead Sciences
Table 9-1: Gilead Sciences Corporate Summary
Table 9-2: Gilead Sciences: Total Company Revenue and Total R&D Spending2011-2015
Figure 9-1: Gilead Sciences: Break-up of Sales by Region, 2015
Figure 9-2: Gilead Sciences: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 9-3: Gilead Sciences: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 9-3: Gilead Sciences: Leading Pharmaceutical Products, 2015 Sales
Table 9-4: Gilead Sciences: Late Stage Product Pipeline
Figure 9-4: Gilead Sciences: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
Table 9-5: Gilead Sciences: Highlighted Corporate Developments
Johnson & Johnson
Table 10-1: Johnson & Johnson Corporate Summary
Table 10-2: Johnson & Johnson: Total Company Revenue and Total R&D Spending 2011-2015
Figure 10-1: Johnson & Johnson: Break-up of Sales by Region, 2015
Figure 10-2: Johnson & Johnson: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 10-3: Johnson & Johnson: Pharmaceutical Segment Sales 2011 through2015 and Forecasted 2025
Table 10-3: Johnson & Johnson: Leading Pharmaceutical Products, 2015 Sales
Table 10-4: Johnson & Johnson: Late Stage Product Pipeline
Figure 10-4: Johnson & Johnson: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 10-5: Highlighted Corporate Developments
GlaxoSmithKline plc
Table 11-1: GlaxoSmithKline Corporate Summary
Table 11-2: GlaxoSmithKline: Total Company Revenue and Total R&D Spending2011-2015
Figure 11-1: GlaxoSmithKline: Break-up of Sales by Region, 2015
Figure 11-2: GlaxoSmithKline: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 11-3: GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through2015 and Forecasted 2025
Table 11-3: GlaxoSmithKline: Leading Pharmaceutical Products, 2015 Sales
Table 11-4: GlaxoSmithKline: Late Stage Product Pipeline
Figure 11-4: GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 11-5: Highlighted Corporate Developments
AstraZeneca plc
Table 12-1: AstraZeneca Corporate Summary
Table 12-2: AstraZeneca: Total Company Revenue and Total R&D Spending2011-2015
Figure 12-1: AstraZeneca: Break-up of Sales by Region, 2015
Figure 12-2: AstraZeneca: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 12-3: AstraZeneca: Pharmaceutical Segment Sales 2011 through 2015
and Forecasted 2025
Table 12-3: AstraZeneca: Leading Pharmaceutical Products, 2015 Sales
Table 12-4: AstraZeneca: Late Stage Product Pipeline
Figure 12-4: AstraZeneca: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013and 2015
Table 12-5: Highlighted Corporate Developments
AbbVie, Inc.
Table 13-1: AbbVie Corporate Summary
Table 13-2: AbbVie: Total Company Revenue and Total R&D Spending 2011-2015
Figure 13-1: AbbVie: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 13-2: AbbVie: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 13-3: AbbVie: Leading Pharmaceutical Products, 2015 Sales
Table 13-4: AbbVie: Late Stage Product Pipeline
Figure 13-3: AbbVie: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 13-5: Highlighted Corporate Developments
Amgen, Inc.
Table 14-1: Amgen Corporate Summary
Table 14-2: Amgen: Total Company Revenue and Total R&D Spending 2011-2015
Figure 14-1: Amgen: Break-up of Sales by Region, 2015
Figure 14-2: Amgen: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 14-3: Amgen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 14-3: Amgen: Leading Pharmaceutical Products, 2015 Sales
Table 14-4: Amgen: Late Stage Product Pipeline
Figure 14-4: Amgen: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 14-5: Highlighted Corporate Developments
TEVA Pharmaceutical Industries, Ltd.
Table 15-1: Teva Pharmaceutical Corporate Summary
Table 15-2: Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2011-2015
Figure 15-1: Teva Pharmaceutical: Break-up of Sales by Region, 2015
Figure 15-2: Teva Pharmaceutical: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 15-3: Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 15-3: Teva Pharmaceutical: Leading Pharmaceutical Products, 2015 Sales
Table 15-4: Teva Pharmaceutical: Late Stage Product Pipeline-Brand
Development
Figure 15-4: Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics)-Comparing 2009, 2011, 2013 and 2015
Table 15-5: Highlighted Corporate Developments
Eli Lilly and Company
Table 16-1: Eli Lilly Corporate Summary
Table 16-2: Eli Lilly’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 16-1: Eli Lilly & Co.: Break-up of Sales by Region, 2015
Figure 16-2: Eli Lilly & Co.: Pharmaceutical Business Performance, 2011-2015
and Forecasted 2025
Figure 16-3: Eli Lilly & Co.: Pharmaceutical Segment Sales 2011 through 2015
and Forecasted 2025
Table 16-3: Eli Lilly & Co.: Leading Pharmaceutical Products, 2015 Sales
Table 16-4: Eli Lilly: Late Stage Product Pipeline
Figure 16-4: Eli Lilly & Co.: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 16-5: Highlighted Corporate Developments
Bristol-Myers Squibb Company
Table 17-1: Bristol-Myers Squibb Corporate Summary
Table 17-2: Bristol-Myers Squibb’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 17-1: Bristol-Myers Squibb: Break-up of Sales by Region, 2015
Figure 17-2: Bristol-Myers Squibb: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025,($millions)
Figure 17-3: Bristol-Myers Squibb: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 17-3: Bristol-Myers Squibb: Leading Pharmaceutical Products, 2015 Sales
Table 17-4: Bristol-Myers Squibb: Late Stage Product Pipeline
Table 17-5: Bristol-Myers Squibb Highlighted Corporate Developments
Novo Nordisk
Table 18-1: Novo Nordisk Corporate Summary
Table 18-2: Novo Nordisk: Total Company Revenue and Total R&D Spending 2011-2015
Figure 18-1: Novo Nordisk: Break-up of Sales by Region, 2015
Figure 18-2: Novo Nordisk: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 18-3: Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 18-3: Novo Nordisk: Leading Pharmaceutical Products, 2015 Sales
Table 18-4: Novo Nordisk: Late Stage Product Pipeline
Figure 18-4: Novo Nordisk: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 18-5: Highlighted Corporate Developments
Bayer AG
Table 19-1: Bayer Corporate Summary
Table 19-2: Bayer’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 19-1: Bayer: Break-up of Sales by Region, 2015
Figure 19-2: Bayer: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 19-3: Bayer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 19-3: Bayer: Leading Pharmaceutical Products, 2015 Sales
Table 19-4: Bayer: Late Stage Product Pipeline
Figure 19-4: Bayer: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 19-5: Highlighted Corporate Developments
Takeda Pharmaceutical Co., Ltd.
Table 20-1: Takeda Corporate Summary
Table 20-1: Takeda’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 20-1: Takeda: Break-up of Sales by Region, 2015
Figure 20-2: Takeda: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 20-3: Takeda: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 20-3: Takeda: Leading Pharmaceutical Products, 2015 Sales
Table 20-4: Takeda Pharmaceutical: Late Stage Product Pipeline
Figure 20-4: Takeda: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 20-5: Highlighted Corporate Developments
Boehringer Ingelheim GmbH
Table 21-1: Boehringer Ingelheim Corporate Summary
Table 21-2: Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2011-2015
Figure 21-1: Boehringer Ingelheim: Break-up of Sales by Region, 2015
Figure 21-2: Boehringer Ingelheim: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 21-3: Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 21-3: Boehringer Ingelheim: Leading Pharmaceutical Products, 2015 Sales
Table 21-4: Boehringer Ingelheim: Late Stage Product Pipeline
Figure 21-4: Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 21-5: Highlighted Corporate Developments
Allergan PLC
Table 22-1: Allergan plc Corporate Summary
Table 22-2: Allergan: Total Company Revenue and Total R&D Spending 2011-2015
Figure 22-1: Allergan: Pharmaceutical Business Performance, 2014-2015 and Forecasted 2025
Figure 22-2: Allergan: Pharmaceutical Segment Sales 2014 - 2015 and Forecasted 2025
Table 22-3: Allergan: Late Stage Product Pipeline-Brand Development
Table 22-4: Allergan: Highlighted Corporate Developments
Astellas Pharma, Inc.
Table 23-1: Astellas Corporate Summary
Table 23-2: Astellas: Total Company Revenue and Total R&D Spending 2011-2015
Figure 23-1: Astellas: Break-up of Sales by Region, 2015
Figure 23-2: Astellas: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 23-3: Astellas: Pharmaceutical Segment Sales 2011 through 2015 and
Forecasted 2025
Table 23-3: Astellas: Leading Pharmaceutical Products, 2015 Sales
Table 23-4: Astellas: Late Stage Product Pipeline
Figure 23-4: Astellas: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 23-5: Highlighted Corporate Developments
Mylan, Inc.
Table 24-1: Mylan Corporate Summary
Table 24-2: Mylan: Total Company Revenue and Total R&D Spending 2011-2015
Figure 24-1: Mylan: Break-up of Sales by Region, 2015
Figure 24-2: Mylan: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 24-3: Mylan: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 24-4: Corporate Development Details
Biogen, Inc.
Table 25-1: Biogen Corporate Summary
Table 25-2: Biogen: Total Company Revenue and Total R&D Spending 2011-2015
Figure 25-1: Biogen: Break-up of Sales by Region, 2015
Figure 25-2: Biogen: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 25-3: Biogen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 25-3: Biogen: Leading Pharmaceutical Products, 2015 Sales
Table 25-4: Biogen: Late Stage Product Pipeline
Figure 25-4: Biogen: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011 and 2013
Table 25-5: Biogen: Highlighted Corporate Developments
Celgene Corporation
Table 26-1: Celgene Corporate Summary
Table 26-2: Celgene: Total Company Revenue and Total R&D Spending 2011-2015
Figure 26-1: Celgene: Break-up of Sales by Region, 2015
Figure 26-2: Celgene: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 26-3: Celgene: Pharmaceutical Segment Sales 2011 through 2015 and
Forecasted 2025
Table 26-3: Celgene: Leading Pharmaceutical Products, 2015 Sales
Table 26-4: Celgene: Late Stage Product Pipeline
Figure 26-4: Celgene: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 26-5: Celgene: Corporate Development Details
Otsuka Pharmaceutical
Table 27-1: Otsuka Corporate Summary
Table 27-2: Otsuka Holdings: Total Company Revenue and Total R&D Spending2011-2015
Figure 27-1: Otsuka Holdings: Break-up of Sales by Region, 2015
Figure 27-2: Otsuka Holdings: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2023
Figure 27-3: Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 27-3: Otsuka Holdings: Leading Pharmaceutical Products, 2015 Sales
Table 27-4: Otsuka Holdings: Late Stage Product Pipeline
Figure 27-4: Otsuka Holdings: Late Stage Product Pipeline by Therapeutic
Area-Comparing 2009, 2011, 2013 and 2015
Table 27-5: Highlighted Corporate Developments
Daiichi Sankyo
Table 28-1: Daiichi Sankyo Corporate Summary
Table 28-2: Daiichi Sankyo: Total Company Revenue and Total R&D Spending2011-2015
Figure 28-1: Daiichi Sankyo: Break-up of Sales by Region, 2015
Figure 28-2: Daiichi Sankyo: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 28-3: Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 28-3: Daiichi Sankyo: Leading Pharmaceutical Products, 2015 Sales
Table 28-4: Daiichi Sankyo: Late Stage Product Pipeline
Figure 28-4: Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 28-5: Highlighted Corporate Developments
Market Summary and Forecast Analysis
Table 29-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
Figure 29-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
Figure 29-2: Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
Figure 29-3: Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
Figure 29-4: Top 5 Neurotherapeutic Companies, 2015 Sales
Figure 29-5: Top 5 Infection Treatment Companies, 2015 Sales
Figure 29-6: Top 5 Oncology Companies, 2015 Sales
Figure 29-6: Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
Figure 29-7: Top 5 Other Drug Companies, 2015 Sales
Figure 29-8: Global Pharmaceutical Market % Change by Therapeutic Segment,2014- 2015
Table 29-2: Top Companies by 2015 Pharmaceutical Sales Growth
Figure 29-9: Global Pharmaceutical Market, Sales Growth by Company, 2014-2015
Table 29-3: Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales2015 Compared to 2011 and 2013
Table 29-4: Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
Table 29-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,2025—based on late stage development projects evaluated
Figure 29-11: Global Pharmaceutical Market Forecast by Therapeutic Segment,2025—based on late stage development projects evaluated
Table 29-6: Evaluating Pharmaceutical Company Growth, 2015-2025

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Daiichi Sankyo
  • Eli Lilly & Co.
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Novartis
  • Novo Nordisk
  • Otsuka Pharmaceutical
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • TEVA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll